How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

1,766 results for

Mycosis Fungoides

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

21. Understanding racial disparities in mycosis fungoides through international collaborative studies. (PubMed)

Understanding racial disparities in mycosis fungoides through international collaborative studies. 30604871 2019 01 25 1365-2133 2019 Jan 03 The British journal of dermatology Br. J. Dermatol. Understanding racial disparities in mycosis fungoides through international collaborative studies. 10.1111/bjd.17598 Geller S S https://orcid.org/0000-0003-1206-1057 Dermatology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center and Weill Cornell Medicine, New York, NY, U.S.A

2019 British Journal of Dermatology

22. Low- vs. Middle-dose Total Skin Electron Beam Therapy for Mycosis Fungoides: An Efficiency-based Retrospective Survey of Skin Response. (Full text)

Low- vs. Middle-dose Total Skin Electron Beam Therapy for Mycosis Fungoides: An Efficiency-based Retrospective Survey of Skin Response. Optimal doses of total skin electron beam therapy for mycosis fungoides remain to be established. Clinical efficiency and adverse effects of middle-dose (25 Gy) vs. low-dose (10-12 Gy) total skin electron beam therapy were retrospectively compared in a series of 14 and 12 mycosis fungoides, respectively. Overall skin response rate was 96.2% (92.9% middle-dose

2019 Acta Dermato-Venereologica

23. Measurement of Quality of Life in Patients with Mycosis Fungoides/Sézary Syndrome Cutaneous T-Cell Lymphoma: Development of an Electronic Instrument. (Full text)

Measurement of Quality of Life in Patients with Mycosis Fungoides/Sézary Syndrome Cutaneous T-Cell Lymphoma: Development of an Electronic Instrument. Although the quality of life (QoL) plays an important role in treatment decision making and clinical management of mycosis fungoides (MF) or Sézary syndrome (SS) subtypes of cutaneous T-cell lymphomas (MF/SS-CTCLs), an MF- or SS-specific measure of QoL does not exist.The objective of this research was to develop and validate the first QoL

2019 Journal of medical Internet research

24. Mycosis fungoides presenting as vulvar plaques. (PubMed)

Mycosis fungoides presenting as vulvar plaques. 30653269 2019 02 27 1468-3083 2019 Jan 17 Journal of the European Academy of Dermatology and Venereology : JEADV J Eur Acad Dermatol Venereol Mycosis fungoides presenting as vulvar plaques. 10.1111/jdv.15429 El Alami J J Department of Dermatology, INSERM U976, Saint-Louis Hospital, APHP, Paris Diderot University, 49100 Angers, Paris, France. Le Corre Y Y Department of Dermatology, University Hospital of Angers, UBL University, Angers, 75010 Paris

2019 Journal of the European Academy of Dermatology and Venereology

25. Epidemiological, clinical, histological, and immunohistochemical study on hypopigmented epitheliotropic T-cell dyscrasia and hypopigmented mycosis fungoides. (PubMed)

Epidemiological, clinical, histological, and immunohistochemical study on hypopigmented epitheliotropic T-cell dyscrasia and hypopigmented mycosis fungoides. Hypopigmented dermatoses, more evident in dark-skinned people, are a frequent cause of consultation. Their etiology includes a wide range of dermatoses, from benign to malignant diseases. The clinical presentation appears very similar between them, making the correct diagnoses and management a challenge.Clinical records (...) and histopathological biopsies were identified and compared in patients of the "Dr. Manuel Gea González" General Hospital throughout a 16-year period with the presumptive diagnosis of hypopigmented epitheliotropic T-cell dyscrasia (HTCD) or hypopigmented mycosis fungoides (HMF). Immunostaining analysis was performed in each specimen, the panel of antibodies used was: CD3, CD4, CD7, CD8, CD20, and CD62L.Thirty cases of 81 patients found in the registries were included in this study. The main age group was formed

2019 International Journal of Dermatology

26. Mycosis fungoides and Sézary syndrome: 2019 update on diagnosis, risk-stratification, and management. (Full text)

Mycosis fungoides and Sézary syndrome: 2019 update on diagnosis, risk-stratification, and management. Cutaneous T-cell lymphomas (CTCL) are a heterogenous group of T-cell neoplasms involving the skin, the majority of which may be classified as Mycosis fungoides (MF) or Sézary syndrome (SS).The diagnosis of MF or SS requires the integration of clinical and histopathologic data.TNMB (tumor, node, metastasis, blood) staging remains the most important prognostic factor in MF/SS and forms the basis

2019 American journal of hematology

27. Regression of Mycosis Fungoides with Large Cell Transformation Following Skin Biopsy. (PubMed)

Regression of Mycosis Fungoides with Large Cell Transformation Following Skin Biopsy. Cutaneous T-cell lymphomas (CTCLs) are a group of mature extranodal T-cell lymphomas, of which mycosis fungoides (MF) is the most common subtype. MF commonly presents as patch-or-plaques on non-sun exposed areas of the body and often follows an indolent clinical course (1). Advanced MF, stage IIb-IV, has a 5-year survival which ranges from 28 to 68%. (2) Large cell transformation (LCT), age greater than 60

2019 Journal of the European Academy of Dermatology and Venereology

28. Exploratory Assessment Of Oxygen Flow Assisted Cutaneous Administration Of Methotrexate For Superficial Basal Cell Carcinoma, Mycosis Fungoides And Extramammary Paget's Disease. (PubMed)

Exploratory Assessment Of Oxygen Flow Assisted Cutaneous Administration Of Methotrexate For Superficial Basal Cell Carcinoma, Mycosis Fungoides And Extramammary Paget's Disease. The molecular weight of methotrexate (MTX) makes cutaneous penetration difficult. Oxygen flow could enhance the skin permeation of MTX diluted in the LP3 carrier system. This pilot study aims to assess the efficacy, safety and tolerance of oxygen-flow-administered (OFA)-LP3-MTX3% for treating superficial skin cancers (...) . Patients with superficial basal cell carcinoma (sBCC)(n=12), extramammary Paget's disease (EMPD)(n=5), mycosis fungoides classic type (CMF) (n=10) and folliculotropic (FMF) (n=6) were included in the study and were treated with 4 weekly applications of OFA-LP3-MTX3%. Photographs and biopsies were performed before (T0) and one month after treatment (T1). At T1, the mean sBCC ECT and EMPD EOSP clinical scores, and the modified CAILS CMF and FMF scores were improved by 77.5±17.1% (p<0.0001), 66.7±22.9% (p

2019 Journal of Investigative Dermatology

29. Twist and Zeb1 expression identify Mycosis fungoides patients with low risk of disease progression. (PubMed)

Twist and Zeb1 expression identify Mycosis fungoides patients with low risk of disease progression. Mycosis fungoides (MF) is the most common cutaneous T-cell lymphoma1 . The clinical course is usually slow and the initial treatment is a skin-directed therapy2,3 . When MF becomes refractory, systemic therapies are needed2,3 . Disease progression is seen in about 30% of MF patients but no undisputable markers are available to identify these patients2,3 . Twist, Zeb1 and Slug are transcription

2019 Journal of the European Academy of Dermatology and Venereology

30. Efficacy of doxycycline in the treatment of early stages of mycosis fungoides: a randomized controlled trial. (PubMed)

Efficacy of doxycycline in the treatment of early stages of mycosis fungoides: a randomized controlled trial. Background: Mycosis fungoides is the most common type of primary cutaneous T cell lymphomas. Doxycycline promoted apoptosis in different human malignant cell lines and in vivo models. Objectives: To test for the therapeutic efficacy of doxycycline in comparison to PUVA in early stages of classic MF and its effect on T cell apoptosis. Methods: Thirty-six patients were randomized

2019 Journal of Dermatological Treatment

31. Poikilodermatous Mycosis Fungoides: Comparative Study of Clinical, Histopathological and Immunohistochemical Features. (PubMed)

Poikilodermatous Mycosis Fungoides: Comparative Study of Clinical, Histopathological and Immunohistochemical Features. Poikilodermatous mycosis fungoides (pMF) is characterized by poikiloderma areas, typically involving the major flexural areas and trunk. Its presentation can be generalized or admixed with other forms of MF. Previous studies fail to correlate the clinical presentation with prognosis and laboratory findings. Some reports show pityriasis lichenoides chronica (PLC) preceding

2019 Dermatology

32. Increased risk of second primary hematologic and solid malignancies in patients with mycosis fungoides: a Surveillance, Epidemiology, and End Results analysis. (PubMed)

Increased risk of second primary hematologic and solid malignancies in patients with mycosis fungoides: a Surveillance, Epidemiology, and End Results analysis. Mycosis fungoides (MF) is associated with increased risk of second primary hematologic malignancies, but its association with second primary solid tumors is less well characterized.This retrospective analysis seeks to assess the risk of being diagnosed with a second primary hematologic or solid malignancy in patients with MF.We performed

2019 Journal of American Academy of Dermatology

33. Outcomes and Prognostic Factors In African American / Black Patients With Mycosis Fungoides And Sézary Syndrome: Retrospective Analysis Of 157 Patients From A Referral Cancer Center. (PubMed)

Outcomes and Prognostic Factors In African American / Black Patients With Mycosis Fungoides And Sézary Syndrome: Retrospective Analysis Of 157 Patients From A Referral Cancer Center. The prevalence of mycosis fungoides / Sézary syndrome (MF/SS) is higher in the African American (AA)/black population compared to Caucasians in the United States and worse outcomes have been observed in AA/black patients.To describe the outcomes and to identify prognostic factors in AA/black patients with MF

2019 Journal of American Academy of Dermatology

34. SHARPIN overexpression promotes TAK1 expression and activates JNKs and NF-κB pathway in Mycosis Fungoides. (Full text)

SHARPIN overexpression promotes TAK1 expression and activates JNKs and NF-κB pathway in Mycosis Fungoides. Mycosis Fungoides (MF) is the most common subtype of cutaneous T-cell lymphomas (CTCL). Shank-associated RH domain-interacting protein (SHARPIN) participates in the initiation and development of multiple tumors. However, the clinical significance of SHARPIN in MF hasn't been investigated. The c-Jun N-terminal kinases (JNKs) pathway is a member of mitogen-activated protein kinases (MAPKs

2019 Experimental Dermatology

35. Revisiting the initial diagnosis and blood staging of Mycosis Fungoides and Sézary Syndrome with the KIR3DL2 marker. (PubMed)

Revisiting the initial diagnosis and blood staging of Mycosis Fungoides and Sézary Syndrome with the KIR3DL2 marker. The early diagnosis of Sézary syndrome is challenging. Loss of CD7 and CD26 expression on CD4 T cells is currently used criteria in the initial diagnosis and staging of Sézary patients.Our goal was to evaluate the respective value of CD26, CD7 and KIR3DL2 expression on CD4+ T-cells and total lymphocytes at initial diagnosis of Sézary syndrome.This prospective study included 254

2019 British Journal of Dermatology

36. The MicroRNA Expression Profile Differs Between Erythrodermic Mycosis Fungoides and Sézary Syndrome. (Full text)

The MicroRNA Expression Profile Differs Between Erythrodermic Mycosis Fungoides and Sézary Syndrome. It is difficult to distinguish erythrodermic mycosis fungoides from Sézary syndrome due to their similar clinical and histological features. The main purpose of this study was to investigate whether microRNA expression profiles in lesional skin could discriminate patients with erythrodermic mycosis fungoides from those with Sézary syndrome. A further aim was to assess whether the microRNA (...) expression profiles in erythrodermic mycosis fungoides skin was more comparable to microRNA expression profiles of Sézary syndrome or early-stage mycosis fungoides. RNA was extracted from diagnostic skin biopsies, followed by quantitative reverse transcription polymerase chain reaction analysis of 383 microRNAs. Twenty-seven microRNAs were significantly differentially expressed between erythro-dermic mycosis fungoides and Sézary syndrome. More-over, erythrodermic mycosis fungoides showed microRNA

2019 Acta Dermato-Venereologica

37. A comparative analysis of histone deacetylase inhibitors for the treatment of mycosis fungoides and Sézary syndrome. (PubMed)

A comparative analysis of histone deacetylase inhibitors for the treatment of mycosis fungoides and Sézary syndrome. 31512229 2019 10 14 1365-2133 2019 Sep 12 The British journal of dermatology Br. J. Dermatol. A comparative analysis of histone deacetylase inhibitors for the treatment of mycosis fungoides and Sézary syndrome. 10.1111/bjd.18522 Papps T T Division of Cancer Medicine, Peter MacCallum Cancer Centre and Sir Peter MacCallum Department of Medical Oncology, University of Melbourne

2019 British Journal of Dermatology

38. FDA Approval Summary: Mogamulizumab-kpkc for Mycosis Fungoides and Sézary Syndrome. (PubMed)

FDA Approval Summary: Mogamulizumab-kpkc for Mycosis Fungoides and Sézary Syndrome. The FDA-approved mogamulizumab-kpkc, a CC chemokine receptor type 4 (CCR4)-directed mAb, in August 2018 for treatment of adult patients with relapsed or refractory mycosis fungoides or Sézary syndrome after at least one prior systemic therapy. Regular approval was based on a randomized, open-label trial that randomized 372 such patients, with a median of 3 prior systemic therapies, to either mogamulizumab-kpkc

2019 Clinical Cancer Research Controlled trial quality: uncertain

39. Pembrolizumab in Relapsed and Refractory Mycosis Fungoides and Sézary Syndrome: A Multicenter Phase II Study. (PubMed)

Pembrolizumab in Relapsed and Refractory Mycosis Fungoides and Sézary Syndrome: A Multicenter Phase II Study. To assess the efficacy of pembrolizumab in patients with advanced relapsed or refractory mycosis fungoides (MF) or Sézary syndrome (SS).CITN-10 is a single-arm, multicenter phase II trial of 24 patients with advanced MF or SS. Patients were treated with pembrolizumab 2 mg/kg every 3 weeks for up to 24 months. The primary end point was overall response rate by consensus global response

2019 Journal of Clinical Oncology

40. Follicular Mycosis Fungoides (FMF): Meta-analysis of improved survival

Follicular Mycosis Fungoides (FMF): Meta-analysis of improved survival Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence: Organisation web address: Timing and effect

2018 PROSPERO

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>